Physician profile
Patrick D Hung
NPI 1164435103
$41,630.33
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $15K · 2021: $542 · 2022: $905 · 2023: $493 · 2024: $7,139 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $2,425 · Food and Beverage: $1,742 · Education: $21.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,855.00 |
| Travel and Lodging | $2,424.88 |
| Food and Beverage | $1,741.85 |
| Education | $21.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23,978.44 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $14,818.14 | 2019-2023 | Entyvio |
| Abbvie INC. | $951.22 | 2020-2025 | |
| Celgene Corporation | $378.78 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $285.75 | 2020-2024 | Stelara, Tremfya, Simponi |
| Intercept Pharmaceuticals, INC. | $230.32 | 2019-2023 | Ocaliva |
| Pfizer INC. | $206.43 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $154.52 | 2019-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.43 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $125.11 | 2021-2023 | |
| Braintree Laboratories, INC. | $65.16 | 2019-2021 | |
| Celltrion USA INC. | $54.95 | 2024-2025 | Vegzelma, Zymfentra |
| Fresenius Kabi USA, LLC | $49.59 | 2023-2024 | Idacio |
| Intra-Sana Laboratories | $49.21 | 2021 | |
| Ardelyx, INC. | $40.72 | 2024 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $33.47 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.43 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.96 | 2022 | |
| Qol Medical, LLC | $19.07 | 2021 | |
| Genzyme Corporation | $13.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.